iValue Partners with eMudhra to Enhance Digital Trust Solutions Across India, SAARC, and SEA Regions
BENGALURU, India, Feb. 25, 2025 /PRNewswire/ -- iValue Group, a leading strategic technology advisor specializing in securing and managing digital applications and data, has been appointed as the authorized distributor for eMudhra Limited, a global leader in PKI-driven Digital Transformation solutions. This partnership covers the India, SAARC, and SEA regions, enhancing digital trust and cybersecurity standards across multiple industries.
Expanding Digital Trust with eMudhra's Comprehensive Cybersecurity Portfolio
eMudhra, accredited by WebTrust as the first and only Indian company, offers a comprehensive cybersecurity portfolio that goes beyond SSL certificates. This includes Public Key Infrastructure (PKI) solutions, Converged Identity Solutions, Certificate Lifecycle Management, and eSignature Workflow Automation. These solutions are fully developed in India, ensuring compliance with local data residency requirements while delivering a secure and seamless digital experience. By leveraging advanced PKI technology and Zero Trust Architecture, eMudhra empowers organizations to safeguard digital interactions, maintain regulatory compliance, and enhance operational efficiency.
Multi-Tier Distribution Model to Accelerate Market Adoption
Under this strategic alliance, iValue Group will operate in a multi-tier distribution model, offering eMudhra's comprehensive digital trust solutions directly to customers and indirectly through its extensive channel partner network. This model is designed to enhance market penetration and accelerate the adoption of advanced cybersecurity solutions across sectors, including BFSI, Government, Healthcare, and Enterprise.
Commenting on the partnership, R Venkatesh, Co-Founder and VP Business Management, iValue Group, stated, "This partnership with eMudhra aligns with iValue's vision of delivering state-of-the-art cybersecurity solutions that combine local innovation with global standards. Our extensive partner network and expertise in the digital security domain will help drive adoption across multiple industries, empowering businesses to enhance their digital interactions with confidence."
Kaushik Srinivasan, Co-Founder, eMudhra, added, "At eMudhra, our mission is to secure digital transactions and empower organizations to build digital trust. Partnering with iValue Group, with its deep-rooted presence and vast channel ecosystem, enables us to reach a broader audience and accelerate digital transformation in the region. This collaboration reinforces our commitment to delivering secure, locally compliant, and future-ready cybersecurity solutions."
Empowering Organizations with End-to-End Digital Security Solutions
By joining forces with eMudhra, iValue Group significantly enhances its cybersecurity portfolio, offering a comprehensive suite of digital identity, authentication, encryption, and workflow automation solutions. This partnership enables businesses to safeguard digital interactions, comply with global security standards, and maintain local data residency, thereby reducing dependency on foreign entities.
About iValue Group
iValue Group is the fastest-growing strategic technology advisor specializing in securing and managing digital applications and data for enterprises in hybrid-cloud environments. With 16 years of expertise, iValue provides customized solution stacks and associated services, collaborating closely with 80+ OEMs, 1000+ partners, and system integrators. Backed by a 500+ strong team, including over 50% technical experts, iValue delivers comprehensive Professional and Managed Services. Its cloud-based Center of Excellence features 25+ integrated solutions, streamlining technology adoption for partners and enterprises.
With a significant presence in SAARC and Southeast Asia, iValue Group blends local insights with global best practices, addressing the business and technical needs of its partners to enhance enterprise security and digital transformation.
For more information, visit www.iValueGroup.com or follow @iValueGroup on LinkedIn.
About eMudhra
eMudhra is a global leader in digital identity and cybersecurity, offering a full suite of digital trust solutions, including Public Key Infrastructure (PKI), Converged Identity Solutions, Certificate Lifecycle Management, and eSignature Workflow Automation. With a focus on ensuring secure digital transactions and information safety, eMudhra serves governments, financial institutions, and enterprises worldwide, with a strong presence in India. Leveraging advanced technologies such as Post Quantum Ready Cryptography and Zero-Trust Identity Governance, eMudhra is at the forefront of future-proof cybersecurity solutions, empowering organizations to build digital trust and achieve compliance with global security standards.
For more information, visit www.emudhra.com | Follow on LinkedIn: https://www.linkedin.com/company/emudhra
View original content:https://www.prnewswire.com/in/news-releases/ivalue-partners-with-emudhra-to-enhance-digital-trust-solutions-across-india-saarc-and-sea-regions-302382267.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
CrowdStrike (CRWD) Expands AWS Partnership to Power AI Security Solutions
CrowdStrike Holdings, Inc. (NASDAQ:CRWD) is one of the . On July 16, Crowdstrike announced an expanded collaboration with Amazon Web Services (AWS) to fast-track AI adoption in cybersecurity and secure AI use. Under the collaboration, Crowdstrike's new tools, the falcon-mcp, which is an MCP server for the CrowdStrike Falcon® platform, and CrowdStrike AI Red Team Services, are available under the new AI Agents and Tools category of AWS Marketplace. These tools will help AWS customers to operationalize agentic AI workflow integrations, as well as safely test and protect AI systems within their existing AWS environment. With AI adoptions accelerating, offering realistic ways to connect models to real-time security operations has become a critical need. Trusted frameworks such as those from Crowdstrike can help companies power their security operations and protect the AI systems those operations depend on. A trust services representative using modern technology for improved financial security. 'Agentic AI is fundamentally changing business of all sizes across every industry – but only secure AI can safely scale to deliver long-term results. With these offerings now available in AWS Marketplace, CrowdStrike is giving customers the power to safely build, test, and run AI-driven security workflows using the same cybersecurity platform trusted to protect the world's most critical environments.' -Daniel Bernard, chief business officer, CrowdStrike. CrowdStrike Holdings, Inc. (NASDAQ:CRWD) is a leader in AI-driven endpoint and cloud workload protection. While we acknowledge the potential of CRWD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. Viatris Chief R&D Officer Philippe Martin said, "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study. Thank you to the patients and investigators who contributed to the trial." The Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions. In June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. The Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. About the MR-139 3001 Phase 3 StudyThe MR-139 3001 Phase 3 trial consisted of a randomized, placebo-controlled, double-masked prospective study, with a total of 477 patients who were randomized to receive either MR-139 or placebo, self-administered to the eyelids twice daily, treated and observed over 12 weeks. For more information on the MR-139 study design, refer to (NCT06400511). About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at and and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter). Forward-Looking StatementsThis press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing; given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study; the Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions; in June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions; and the Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; longer review, response and approval times as a result of evolving regulatory priorities and reductions in personnel at health agencies; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. View original content to download multimedia: SOURCE Viatris Inc. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
PR Newswire Empowers Brands for AI Search and Strategic Communications with Multichannel Content Amplification
Key features for optimizing content in an AI-driven search environment NEW YORK, July 18, 2025 /PRNewswire/ -- As Large Language Models (LLMs) rapidly transform the search landscape, PR Newswire is empowering communicators to excel through its advanced Multichannel Amplification™ services. PR Newswire helps organizations publish once and reach everywhere, enhancing topical authority and shaping favorable AI-generated summaries. Key Features of PR Newswire's Multichannel Amplification services: Topical Authority: Build and reinforce your brand's presence in authoritative search results by leveraging PR Newswire's industry-leading distribution network, designed to surface expert-driven content across major search engines and media outlets. This is crucial for establishing your brand as a trusted source in an LLM-driven search environment. AI-Friendly Optimization: Structure and distribute press releases that are easily understood and surfaced by AI models, including LLMs. This boosts your brand's visibility and positioning in AI-generated answers and summaries, ensuring your message is accurately interpreted and presented in the evolving search ecosystem. One Message, Multiple Missions: Whether it's media relations, investor updates, brand awareness, or thought leadership, PR Newswire enables you to fulfill multiple communications objectives through a single, strategically crafted piece of content, optimized for how LLMs process information. "PR Newswire's platform is built for today's evolving media landscape, deeply impacted by the rise of LLMs," said Jeff Hicks, Chief Product and Technology Officer at PR Newswire. "We're not just distributing press releases – we're giving brands the tools to influence conversations, rank as topical authorities, and be found in the ways people are searching today, which increasingly means through LLM-powered interfaces." Helpful resources Ready to enhance your brand's visibility in the age of AI? Learn more about PR Newswire's Multichannel Amplification services: Watch PR Newswire's recent on-demand webinar, "From Keywords to Conversations: How AI Search is Reshaping PR," to explore how smart distribution can maximize visibility in the age of AI and LLMs: About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at View original content to download multimedia: SOURCE PR Newswire
